Createrna Receives IND Approval for Novel Class 1 Drug QR055453D Tablets for Idiopathic Pulmonary Fibrosis (IPF)

Wuhan, China — Createrna (Wuhan Createrna Science and Technology Development Co., Ltd.) announced that QR055453D Tablets, a novel Class 1 drug independently developed by the company, has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) of China for the treatment of idiopathic pulmonary fibrosis (IPF).

IPF is a chronic, progressive, fibrotic interstitial pneumonia of unknown etiology that predominantly affects the elderly population. The disease is characterized by progressive dyspnea and deteriorating pulmonary function, carries a poor prognosis, and is classified as a rare disease. Epidemiological data indicate that the median survival following diagnosis is only 3 to 5 years, posing a serious threat to patients’ lives and health.

Current standard-of-care relies primarily on antifibrotic and antioxidant agents such as pirfenidone and nintedanib. However, existing therapies offer limited efficacy in slowing disease progression and are associated with significant adverse effects, underscoring the urgent unmet need for safer and more effective therapeutic options.

QR055453D Tablets act by precisely blocking key pathogenic signaling pathways involved in pulmonary fibrosis. The compound reduces alveolar epithelial cell apoptosis, inhibits fibroblast chemotaxis and proliferation, suppresses collagen secretion, and reduces the anti-apoptotic capacity of fibroblasts. These actions collectively ameliorate excessive extracellular matrix (ECM) deposition in lung tissue, thereby attenuating fibrotic progression through multiple mechanistic pathways.

Preclinical studies demonstrate that QR055453D Tablets exhibit significant advantages in efficacy, pharmacokinetics, and safety compared to drugs targeting the same molecular pathway.

This IND approval further expands Createrna’s antifibrotic innovative drug pipeline. The company will actively advance clinical development of QR055453D Tablets with the goal of delivering a superior therapeutic option for IPF patients at the earliest opportunity.